Edgar Filing: DelMar Pharmaceuticals, Inc. - Form 4

DelMar Phar Form 4 July 23, 2015	maceuticals, Inc.									
FORM	1 /							OMB AI	PPROVAL	
	UNITEDSTA		ITIES A hington,			IGE (COMMISSION	OMB Number:	3235-0287	
Section 16. Form 4 or			CHANGES IN BENEFICIAL OWN SECURITIES					Expires: Estimated a burden hou response	~	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type F	Responses)									
		Symbol	2. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc.				5. Relationship of Reporting Person(s) to Issuer			
		[DMPI]		,			(Chec	k all applicable	e)	
(Last) (First) (Middle) 3. Date of (Month/D: SUITE 720-999 WEST 07/22/20 BROADWAY			-			X DirectorX 10% Owner X Officer (give title Other (specify below) Chief Scientific Officer				
			endment, Date Original nth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
VANCOUV	'ER, A1 V5Z 1K5						Form filed by M Person			
(City)	(State) (Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A (Month/Day/Year) Ex an (M	xecution Date, if	3. Transactic Code (Instr. 8) Code V	4. Securit on(A) or Dis (D) (Instr. 3, 4 Amount	sposed	of	Securities	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	07/22/2015		P	75,000	A	\$ 0.6	3,027,542	I	See Note	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercis Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and -	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	\$ 0.75	07/22/2015		Р	75,000	07/22/2015	07/22/2020	Common Stock	75,000

Edgar Filing: DelMar Pharmaceuticals, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
r g to to to to to	Director	10% Owner	Officer	Other		
Brown Dennis M SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	X	Х	Chief Scientific Officer			
••						

Signatures

/s/ Dennis	07/23/2015			
Brown	0772572015			
<u>**</u> Signature of Reporting Person	Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Includes 1,377,542 shares of the Issuer's common stock owned directly by Reporting Person and 1,650,000 shares of the Issuer's common (1) stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive

power over its shares. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.